TG THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
TG THERAPEUTICS, INC. (TGTX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.00 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-27
- TG THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2019-03-31 was $6.90.
- TG THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2015-03-31 was $0.00.
- TG THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2014-03-31 was $0.00.
- TG THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2013-03-31 was $0.00.
- TG THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $0.00.
- TG THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $0.00.
- TG THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- TG THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $7.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-27 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-27 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-27 | |||
| 2022-12-31 | $7.00 10-K · filed 2025-03-03 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $8.21 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $6.50 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $6.90 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $6.90 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $6.90 10-Q · filed 2019-05-10 | |||
| 2018-09-30 | $11.65 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $11.56 10-Q · filed 2018-08-09 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $0.00 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-14 | |||
| 2014-06-30 | $0.00 10-Q · filed 2014-07-24 | |||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-14 | |||
| 2013-12-31 | $0.00 10-K · filed 2015-03-16 | |||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-14 | |||
| 2013-06-30 | $0.00 10-Q · filed 2013-08-09 | |||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-14 | |||
| 2012-12-31 | $4.40 10-K · filed 2014-03-07 | |||
| 2012-09-30 | $4.40 10-Q · filed 2012-11-14 | |||
| 2012-06-30 | $0.00 10-Q/A · filed 2012-09-07 | |||
| 2011-12-31 | $0.00 10-K · filed 2013-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |